Skip to main content

Select Drug Profiles

Exkivity Novel Oral Targeted Therapy Approved for Metastatic NSCLC with EGFR Exon 20 Insertion Mutations

Tivdak First Antibody–Drug Conjugate FDA Approved for Recurrent or Metastatic Cervical Cancer

Welireg FDA Approved for 3 Tumor Types Associated with von Hippel-Lindau Disease

Jakafi a New Treatment Option for Chronic Graft-versus-Host Disease

Rezurock Novel Oral Therapy FDA Approved for Chronic Graft-versus-Host Disease

Tabrecta (Capmatinib) First FDA-Approved Drug for Metastatic NSCLC with MET Exon 14 Skipping Mutation

Loretta Fala

Ukoniq (Umbralisib) FDA Approved for Adults with Relapsed or Refractory Marginal-Zone Lymphoma or Follicular Lymphoman

Loretta Fala

Jemperli (Dostarlimab) First Immunotherapy Approved for Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer

Loretta Fala

Abecma (Idecabtagene Vicleucel) First-in-Class BCMA-Directed CAR T-Cell Therapy Approved for Relapsed or Refractory Multiple Myeloma

Loretta Fala

Post-Pandemic Physician Leadership

David B. Nash, MD, MBA

David B. Nash, MD, MBA

Page 19 of 244
Results 181 - 190 of 2438